Showing results (1-10 of 20) with videos related to
Sort By:
Pageof 2
Bioinformatics (Oxford, England)|October 13, 2006
Survival analysis of longitudinal microarraysNatasa Rajicic, Dianne M Finkelstein, David A Schoenfeld, et al.Statistics in Medicine|July 21, 2009
Analysis of the relationship between longitudinal gene expressions and ordered categorical event dataNatasa Rajicic, Dianne M Finkelstein, David A Schoenfeld, et al.Statistics in Medicine|January 10, 2013
A mathematical model for maximizing the value of phase 3 drug development portfolios incorporating budget constraints and riskNitin R Patel, Suresh Ankolekar, Zoran Antonijevic, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|June 24, 2004
Occult hepatitis B in HIV-infected patientsNorah J Shire, Susan D Rouster, Natasa Rajicic, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 8, 2002
Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials GroupKenneth E Sherman, Susan D Rouster, Raymond T Chung, et al.Statistics in Medicine|March 12, 2011
A test for the relationship between a time-varying marker and both recovery and progression with missing dataDavid A Schoenfeld, Natasa Rajicic, Linda H Ficociello, et al.Health and Quality of Life Outcomes|October 11, 2012
Psychometric assessment of the Injection Pen Assessment Questionnaire (IPAQ): measuring ease of use and preference with injection pens for human growth hormoneAndreas M Pleil, Miriam Kimel, Julie McCormack, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|August 13, 2010
Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2W David Hardy, Roy M Gulick, Howard Mayer, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|December 17, 2009
CD4+ T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2David M Asmuth, James Goodrich, David A Cooper, et al.Plos One|October 16, 2010
Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patientsNicholas Funderburg, Magdalena Kalinowska, James Eason, et al.Pageof 2